Seven Days In March: NDA-BLA and ANDA Approval Output Diverged As Coronavirus Teleworking Began
New drug approvals dropped, likely because of a new focus on COVID-19 treatments, while generic drug approvals increased.
You may also be interested in...
Likelihood of an on-time decision on a biosimilar application dropped significantly during the first nine months of the pandemic and declined a bit for new and generic drug applications. FDA says BsUFA review performance is function of program's small sample size.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Productivity remains high as full ANDA approvals reached a FY 2020 peak and complete responses dropped to another low in June.